Vladimı́r Kryštof

5.1k total citations · 1 hit paper
160 papers, 4.2k citations indexed

About

Vladimı́r Kryštof is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Vladimı́r Kryštof has authored 160 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Molecular Biology, 64 papers in Oncology and 59 papers in Organic Chemistry. Recurrent topics in Vladimı́r Kryštof's work include Cancer-related Molecular Pathways (51 papers), Advanced Breast Cancer Therapies (23 papers) and Chronic Lymphocytic Leukemia Research (22 papers). Vladimı́r Kryštof is often cited by papers focused on Cancer-related Molecular Pathways (51 papers), Advanced Breast Cancer Therapies (23 papers) and Chronic Lymphocytic Leukemia Research (22 papers). Vladimı́r Kryštof collaborates with scholars based in Czechia, Germany and Austria. Vladimı́r Kryštof's co-authors include Miroslav Strnad, Radek Jorda, Radek Zbořil, Renata Večeřová, Jana Soukupová, Libor Kvı́tek, Petr Hamal, Milan Kolář, Aleš Panáček and Robert Prucek and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Biomaterials.

In The Last Decade

Vladimı́r Kryštof

150 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antifungal activity of silver nanoparticles against Candida spp.

2009 788 citations Vladimı́r Kryštof et al. profile →

Peers

Countries citing papers authored by Vladimı́r Kryštof

Since Specialization

Citations

This map shows the geographic impact of Vladimı́r Kryštof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vladimı́r Kryštof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vladimı́r Kryštof more than expected).

Fields of papers citing papers by Vladimı́r Kryštof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vladimı́r Kryštof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vladimı́r Kryštof. The network helps show where Vladimı́r Kryštof may publish in the future.

Co-authorship network of co-authors of Vladimı́r Kryštof

This figure shows the co-authorship network connecting the top 25 collaborators of Vladimı́r Kryštof. A scholar is included among the top collaborators of Vladimı́r Kryštof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vladimı́r Kryštof. Vladimı́r Kryštof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib 2025 ·Pharmaceuticals ·(unknown), (unknown), Gladys Sepúlveda, (unknown), (unknown), Vladimı́r Kryštof, Miroslav Strnad, (unknown), Javier Echeverría, Christian Espinosa‐Bustos, (unknown), Jiao Luo, Jaime Mella, Cristian O. Salas	0
2	Synthesis and photodynamic activity of new 5‐[(E)‐2‐(3‐alkoxy‐1‐phenyl‐1H‐pyrazol‐4‐yl)ethenyl]‐2‐phenyl‐3H‐indoles 2024 ·Archiv der Pharmazie ·(unknown), Eva Řezníčková, (unknown), (unknown), (unknown), (unknown), Asta Žukauskaitė, Vladimı́r Kryštof, Algirdas Šačkus	2
3	Identification of novel dithiocarbamate-copper complexes targeting p97/NPL4 pathway in cancer cells 2023 ·European Journal of Medicinal Chemistry ·(unknown), Zdeněk Škrott, Dušana Majera, Pavel Štarha, Vladimı́r Kryštof, Martin Mistrík	2
4	2,4-Diaryl-pyrimido[1,2-a]benzimidazole derivatives as novel anticancer agents endowed with potent anti-leukemia activity: Synthesis, biological evaluation and kinase profiling 2023 ·European Journal of Medicinal Chemistry ·Moataz A. Shaldam, (unknown), Radwan El‐Haggar, (unknown), Taghreed A. Majrashi, Eslam B. Elkaeed, Nicolas Masurier, Vladimı́r Kryštof, Haytham O. Tawfik, Wagdy M. Eldehna	19
5	Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-b]pyridazine Derivatives Identified by Scaffold Hopping 2023 ·Journal of Medicinal Chemistry ·(unknown), Eva Řezníčková, (unknown), Radek Jorda, Milan Dejmek, (unknown), Michal Šála, (unknown), Martin Dračínský, (unknown), (unknown), (unknown), Karel Chalupský, (unknown), Tomáš Gucký, Helena Mertlíková‐Kaiserová, Pavel Klener, Radim Nencka, Vladimı́r Kryštof	8
6	Design and synthesis of novel 1,2,4-triazolo[4,3-b]pyridazine derivatives with anti-cancer activity 2023 ·Journal of Molecular Structure ·(unknown), (unknown), (unknown), (unknown), Eva Řezníčková, (unknown), Vladimı́r Kryštof, Katya Govender, (unknown), (unknown), Mahesh B. Palkar, (unknown), Rajshekhar Karpoormath	6
7	Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7 2023 ·Biomedicine & Pharmacotherapy ·(unknown), Libor Havlı́ček, (unknown), Jana Škerlová, (unknown), Tomáš Pospíšil, Eva Řezníčková, Pavlína Řezáčová, Radek Jorda, Vladimı́r Kryštof	7
8	Development of pyrimidine-cinnamamide hybrids as potential anticancer agents: A rational design approach 2022 ·Journal of Molecular Structure ·(unknown), (unknown), (unknown), (unknown), (unknown), Vladimı́r Kryštof, (unknown), (unknown), Rajshekhar Karpoormath	3
9	Synthesis and Structural Optimization of 2,7,9-Trisubstituted purin-8-ones as FLT3-ITD Inhibitors 2022 ·International Journal of Molecular Sciences ·(unknown), (unknown), Radek Jorda, (unknown), (unknown), Eva Řezníčková, (unknown), (unknown), (unknown), Petr Cankař, Vladimı́r Kryštof	1
10	3,5,7-Substituted Pyrazolo[4,3-d]Pyrimidine Inhibitors of Cyclin-Dependent Kinases and Cyclin K Degraders 2022 ·Journal of Medicinal Chemistry ·Radek Jorda, Libor Havlı́ček, (unknown), (unknown), Tomáš Pospíšil, (unknown), Jana Škerlová, Jiřı́ Grúz, (unknown), Pavel Klener, Pavlína Řezáčová, Miroslav Strnad, Vladimı́r Kryštof	25
11	Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure 2021 ·European Journal of Medicinal Chemistry ·Josef Jansa, Radek Jorda, Jana Škerlová, Petr Pachl, (unknown), Eva Řezníčková, (unknown), Tomáš Gucký, Pavlína Řezáčová, Antonı́n Lyčka, Vladimı́r Kryštof	10
12	1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton’s tyrosine kinase 2020 ·European Journal of Medicinal Chemistry ·(unknown), Radek Jorda, (unknown), Miroslav Soural, Vladimı́r Kryštof	11
13	CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells 2020 ·Cell Death and Disease ·(unknown), Kateřina Growková, (unknown), (unknown), (unknown), Amandine Verlande, Radek Jorda, Vladimı́r Kryštof, (unknown), Panagiotis Alexiou, Vladimír Rotrekl, Stjepan Uldrijan	24
14	Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation 2020 ·European Journal of Medicinal Chemistry ·Mohamed A. Said, Wagdy M. Eldehna, Alessio Nocentini, (unknown), Alessandro Bonardi, Abdullah A. Elgazar, Vladimı́r Kryštof, Dalia H. Soliman, Hatem A. Abdel‐Aziz, Paola Gratteri, Sahar M. Abou‐Seri, Claudiu T. Supuran	58
15	3,5,7-Substituted Pyrazolo[4,3-d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models 2019 ·Journal of Medicinal Chemistry ·Radek Jorda, Libor Havlı́ček, (unknown), (unknown), (unknown), Md. Mahmudul Alam, Jana Škerlová, (unknown), (unknown), Tomáš Pospíšil, Jitka Široká, Lubor Urbánek, Petr Pachl, Pavlína Řezáčová, Miroslav Strnad, Pavel Klener, Vladimı́r Kryštof	21
16	3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights 2019 ·European Journal of Medicinal Chemistry ·Mahmoud F. Abo-Ashour, Wagdy M. Eldehna, Alessio Nocentini, Alessandro Bonardi, Silvia Bua, Hany S. Ibrahim, Mahmoud M. Elaasser, Vladimı́r Kryštof, Radek Jorda, Paola Gratteri, Sahar M. Abou‐Seri, Claudiu T. Supuran	82
17	Novel fluorinated benzimidazole-based scaffolds and their anticancer activity in vitro 2016 ·Journal of Fluorine Chemistry ·(unknown), Mark Edgar, M.R.J. Elsegood, Lynne Horsburgh, Vladimı́r Kryštof, (unknown), (unknown), Simon J. Teat, (unknown), George W. Weaver, (unknown)	23
18	Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance 2013 ·Molecular Cancer Therapeutics ·(unknown), Markus Grubinger, Eva Řezníčková, Thomas S. Weiß, Hans Rotheneder, Walter Miklos, Walter Berger, Radek Jorda, Marek Zatloukal, Tomáš Gucký, Miroslav Strnad, Vladimı́r Kryštof, Wolfgang Mikulits	27
19	Inhibitors of Cyclin-dependent Kinases 2001 ·Chemické listy ·Vladimı́r Kryštof, Miroslav Strnad	1
20	Metabolism of olomoucine, roscovitine, and bohemine in small laboratory rodents 1998 ·Cellular & Molecular Biology Letters ·(unknown), Jozef Veselý, Karel Lemr, Jan Hanuš, Libor Havlı́ček, (unknown), Vladimı́r Kryštof, Jitka Ulrichová, (unknown), (unknown), (unknown), Hana Kolářová, Miroslav Strnad, René Lenobel	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact